Terminated INTERVENTIONAL NCT05430360

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors (GT201)

Single-center, Single-arm Phase I Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Sponsor: Grit Biotechnology

Conditions Solid Tumor

Interventions GT201

Updated 7 times since 2022 Last updated: Apr 22, 2026 Started: Jan 4, 2022 Primary completion: Dec 30, 2025 Completion: Dec 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated from a business perspective.

Other terminated trials from Grit Biotechnology

See all terminations from Grit Biotechnology

Other Solid Tumor trials with similar outcome

Browse all Solid Tumor trials

This observational or N/A phase trial investigates Solid Tumor and is currently terminated or withdrawn. Grit Biotechnology leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Apr 28, 2026 — Present [daily]

Terminated

Status: Recruiting → Terminated · Phase: PHASE1 → None
Mar 2025 — Apr 2026 [monthly]

Recruiting PHASE1
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Jul 2022 — Nov 2023 [monthly]

Recruiting PHASE1

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

This study is a single-center, single-arm phase I clinical trial. A total of 30 subjects (20 evaluable cases are expected) from 1 cohort will be enrolled in this study. An "autologous tumor-infiltrating lymphocyte therapy" dosing regimen consisting of lymphodepleting chemotherapy (FC regimen: cyclophosphamide + fludarabine), infusion of autologous tumor-infiltrating lymphocyte injection, and interleukin-2 injection will be used.The study process is divided into: screening period, sampling and production period, clearing and chemotherapy period, treatment and observation period, and follow-up period

Contact Information

Sponsor contact:

Grit Biotechnology

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China